GlassScriptPhysician profile
Vadim Kushnerik
NPI 1740244771
$5,473.62
in general payments reported to CMS, 2019-2025
20 companies · $40.06 in 2025
The $40.06 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,306 · 2020: $569 · 2021: $684 · 2022: $1,088 · 2023: $1,358 · 2024: $429 · 2025: $40.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,151.60 | 2019-2023 | Proclaim, Prodigy, Octrode |
| Amgen INC. | $537.53 | 2019-2021 | |
| Medtronic, INC. | $393.05 | 2021-2024 | Intellis Adaptivestim |
| Scilex Pharmaceuticals INC. | $245.47 | 2019-2025 | Ztlido |
| Medtronic USA, INC. | $223.09 | 2019 | |
| Forte Bio-Pharma LLC | $207.04 | 2023-2024 | Prolate, Nalocet |
| Boston Scientific Corporation | $184.38 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Takeda Pharmaceuticals U.S.A., INC. | $107.07 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $79.59 | 2023 | Horizant |
| Arbor Pharmaceuticals, INC. | $68.21 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.92 | 2022-2023 | Relistor |
| Collegium Pharmaceutical, INC. | $37.31 | 2019 | |
| Pfizer INC. | $35.46 | 2020 | |
| Redhill Biopharma INC. | $31.25 | 2020 | |
| Daiichi Sankyo INC. | $24.51 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $23.73 | 2019 | |
| Valinor Pharma, LLC | $22.04 | 2025 | Movantik |
| Tersera Therapeutics LLC | $21.21 | 2019 | |
| Assertio Therapeutics, INC. | $20.04 | 2019 | |
| Depuy Synthes Sales INC. | $18.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vadim Kushnerik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.